Information de reference pour ce titreAccession Number: | 00002700-201001000-00014.
|
Author: | Artandi, Steven E.; DePinho, Ronald A. 1,*
|
Institution: | Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA (1)Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
|
Title: | |
Source: | Carcinogenesis. 31(1):9-18, January 2010.
|
Abstract: | Myriad genetic and epigenetic alterations are required to drive normal cells toward malignant transformation. These somatic events commandeer many signaling pathways that cooperate to endow aspiring cancer cells with a full range of biological capabilities needed to grow, disseminate and ultimately kill its host. Cancer genomes are highly rearranged and are characterized by complex translocations and regional copy number alterations that target loci harboring cancer-relevant genes. Efforts to uncover the underlying mechanisms driving genome instability in cancer have revealed a prominent role for telomeres. Telomeres are nucleoprotein structures that protect the ends of eukaryotic chromosomes and are particularly vulnerable due to progressive shortening during each round of DNA replication and, thus, a lifetime of tissue renewal places the organism at risk for increasing chromosomal instability. Indeed, telomere erosion has been documented in aging tissues and hyperproliferative disease states-conditions strongly associated with increased cancer risk. Telomere dysfunction can produce the opposing pathophysiological states of degenerative aging or cancer with the specific outcome dictated by the integrity of DNA damage checkpoint responses. In most advanced cancers, telomerase is reactivated and serves to maintain telomere length and emerging data have also documented the capacity of telomerase to directly regulate cancer-promoting pathways. This review covers the role of telomeres and telomerase in the biology of normal tissue stem/progenitor cells and in the development of cancer.
(C) Copyright Oxford University Press 2010.
|
References: | 1. Palm W, et al. How shelterin protects mammalian telomeres. Annu. Rev. Genet. 2008;42:301-334
2. Griffith JD, et al. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503-514
3. van Steensel B, et al. TRF2 protects human telomeres from end-to-end fusions. Cell 1998;92:401-413
4. Celli GB, et al. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat. Cell Biol. 2005;7:712-718
5. van Steensel B, et al. Control of telomere length by the human telomeric protein TRF1. Nature 1997;385:740-743
6. Smogorzewska A, et al. Control of human telomere length by TRF1 and TRF2. Mol. Cell. Biol. 2000;20:1659-1668
7. Sfeir A, et al. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell 2009;138:90-103
8. Kim SH, et al. TIN2, a new regulator of telomere length in human cells. Nat. Genet. 1999;23:405-412
9. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100-2110
10. Li B, et al. Identification of human Rap1: implications for telomere evolution. Cell 2000;101:471-483
11. Bae NS, et al. A RAP1/TRF2 complex inhibits nonhomologous end-joining at human telomeric DNA ends. Mol. Cell 2007;26:323-334
12. Sarthy J, et al. Human RAP1 inhibits non-homologous end joining at telomeres. EMBO J. 2009;28:3390-3399
13. Baumann P, et al. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 2001;292:1171-1175
14. Ye JZ, et al. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. Genes Dev. 2004;18:1649-1654
15. Liu D, et al. PTOP interacts with POT1 and regulates its localization to telomeres. Nat. Cell Biol. 2004;6:673-680
16. Hockemeyer D, et al. POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. EMBO J. 2005;24:2667-2678
17. Hockemeyer D, et al. Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell 2006;126:63-77
18. Wu L, et al. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 2006;126:49-62
19. Hockemeyer D, et al. Telomere protection by mammalian Pot1 requires interaction with Tpp1. Nat. Struct. Mol. Biol. 2007;14:754-761
20. Loayza D, et al. POT1 as a terminal transducer of TRF1 telomere length control. Nature 2003;424:1013-1018
21. Wang F, et al. The POT1-TPP1 telomere complex is a telomerase processivity factor. Nature 2007;445:506-510
22. Xin H, et al. TPP1 is a homologue of ciliate TEBP-beta and interacts with POT1 to recruit telomerase. Nature 2007;445:559-562
23. Hayflick L, et al. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961;25:585-621
24. Harley CB, et al. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460
25. Shay JW, et al. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res. 1991;196:33-39
26. Hara E, et al. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Commun. 1991;179:528-534
27. Counter CM, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11:1921-1929
28. Bodnar AG, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998;279:349-352
29. Counter CM, et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl Acad. Sci. USA 1998;95:14723-14728
30. Greider CW, et al. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989;337:331-337
31. Lingner J, et al. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997;276:561-567
32. Nakamura TM, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959
33. Meyerson M, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-795
34. Weinrich SL, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Genet. 1997;17:498-502
35. Mitchell JR, et al. A box H/ACA small nucleolar RNA-like domain at the human telomerase RNA 3' end. Mol. Cell. Biol. 1999;19:567-576
36. Chen JL, et al. Secondary structure of vertebrate telomerase RNA. Cell 2000;100:503-514
37. Matera AG, et al. Non-coding RNAs: lessons from the small nuclear and small nucleolar RNAs. Nat. Rev. Mol. Cell Biol. 2007;8:209-220
38. Cioce M, et al. Cajal bodies: a long history of discovery. Annu. Rev. Cell Dev. Biol. 2005;21:105-131
39. Zhu Y, et al. Telomerase RNA accumulates in Cajal bodies in human cancer cells. Mol. Biol. Cell 2004;15:81-90
40. Jady BE, et al. Human telomerase RNA and box H/ACA scaRNAs share a common Cajal body-specific localization signal. J. Cell Biol. 2004;164:647-652
41. Tomlinson RL, et al. Cell cycle-regulated trafficking of human telomerase to telomeres. Mol. Biol. Cell 2006;17:955-965
42. Cristofari G, et al. Human telomerase RNA accumulation in Cajal bodies facilitates telomerase recruitment to telomeres and telomere elongation. Mol. Cell 2007;27:882-889
43. Mitchell JR, et al. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999;402:551-555
44. Cohen SB, et al. Protein composition of catalytically active human telomerase from immortal cells. Science 2007;315:1850-1853
45. Venteicher AS, et al. Identification of ATPases pontin and reptin as telomerase components essential for holoenzyme assembly. Cell 2008;132:945-957
46. Venteicher AS, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009;323:644-648
47. Tycowski KT, et al. A conserved WD40 protein binds the Cajal body localization signal of scaRNP particles. Mol. Cell 2009;34:47-57
48. Kim NW, et al. Specific association of human telomerase activity 965 with immortal cells and cancer. Science 1994;266:2011-2015
49. Yui J, et al. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. Blood 1998;91:3255-3262
50. Liu K, et al. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc. Natl Acad. Sci. USA 1999;96:5147-5152
51. Forsyth NR, et al. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation 2002;69:188-197
52. Bachor C, et al. Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. J. Cancer Res. Clin. Oncol. 1999;125:453-460
53. Ramirez RD, et al. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J. Invest. Dermatol. 1997;108:113-117
54. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872
55. Breault DT, et al. Generation of mTert-GFP mice as a model to identify and study tissue progenitor cells. Proc. Natl Acad. Sci. USA 2008;105:10420-10425
56. Greenberg RA, et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999;18:1219-1226
57. Wu KJ, et al. Direct activation of TERT transcription by c-MYC. Nat. Genet. 1999;21:220-224
58. Kyo S, et al. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008;99:1528-1538
59. Kim JH, et al. Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev. 2005;19:776-781
60. Blasco MA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34
61. Lee HW, et al. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:569-574
62. Hande MP, et al. Telomere length dynamics and chromosomal instability in cells derived from telomerase null mice. J. Cell Biol. 1999;144:589-601
63. Rudolph KL, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999;96:701-712
64. Wong KK, et al. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat. Genet. 2000;26:85-88
65. Allsopp RC, et al. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. Blood 2003;102:517-520
66. Choudhury AR, et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat. Genet. 2007;39:99-105
67. Hemann MT, et al. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001;107:67-77
68. Samper E, et al. Restoration of telomerase activity rescues chromosomal instability and premature aging in Terc-/- mice with short telomeres. EMBO Rep. 2001;2:800-807
69. Krizhanovsky V, et al. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb. Symp. Quant.Biol. 2008;73:513-522
70. Chin L, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538
71. Karlseder J, et al. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999;283:1321-1325
72. Takai H, et al. DNA damage foci at dysfunctional telomeres. Curr. Biol. 2003;13:1549-1556
73. d'Adda di Fagagna F, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003;426:194-198
74. Denchi EL, et al. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007;448:1068-1071
75. Guo X, et al. Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J. 2007;26:4709-4719
76. Brown JP, et al. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997;277:831-834
77. Herrera E, et al. Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J. 1999;18:2950-2960
78. Garinis GA, et al. DNA damage and ageing: new-age ideas for an age-old problem. Nat. Cell Biol. 2008;10:1241-1247
79. Ayouaz A, et al. Telomeres: hallmarks of radiosensitivity. Biochimie 2008;90:60-72
80. Tyner SD, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002;415:45-53
81. Quelle DE, et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000
82. Kim WY, et al. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-275
83. Pomerantz J, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-723
84. Kamijo T, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA 1998;95:8292-8297
85. Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997;91:649-659
86. Serrano M, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37
87. Greenberg RA, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999;97:515-525
88. Khoo CM, et al. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse. Proc. Natl Acad. Sci. USA 2007;104:3931-3936
89. Rudolph KL, et al. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 2001;28:155-159
90. Jaskelioff M, et al. Telomerase deficiency and telomere dysfunction inhibit mammary tumors induced by polyomavirus middle T oncogene. Oncogene 2009
91. Balmain A, et al. Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 1984;307:658-660
92. Gonzalez-Suarez E, et al. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 2000;26:114-117
93. Feldser DM, et al. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007;11:461-469
94. Cosme-Blanco W, et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 2007;8:497-503
95. Land H, et al. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983;304:596-602
96. Hahn WC, et al. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-468
97. Elenbaas B, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001;15:50-65
98. Dajee M, et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421:639-643
99. Wu M, et al. Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc. Natl Acad. Sci. USA 2009;106:7022-7027
100. Chang S, et al. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 2003;17:88-100
101. Harvey M, et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 1993;5:225-229
102. Jacks T, et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994;4:1-7
103. Kastan MB, et al. Cell-cycle checkpoints and cancer. Nature 2004;432:316-323
104. Artandi SE, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-645
105. Windle B, et al. A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev. 1991;5:160-174
106. O'Hagan RC, et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell 2002;2:149-155
107. Maser RS, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007;447:966-971
108. Smogorzewska A, et al. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol 2005;12:1635
109. Keegan CE, et al. Urogenital and caudal dysgenesis in adrenocortical dysplasia (acd) mice is caused by a splicing mutation in a novel telomeric regulator. Hum. Mol. Genet. 2005;14:113-123
110. Vlangos CN, et al. Caudal regression in adrenocortical dysplasia (acd) mice is caused by telomere dysfunction with subsequent p53-dependent apoptosis. Dev. Biol. 2009;334:418-428
111. Else T, et al. Genetic p53deficiency partially rescues the adrenocortical dysplasia (acd) phenotype at the expense of increased tumorigenesis. Cancer Cell 2009;15:465-476
112. Armitage P, et al. The age distribution of cancer and a multi-stage theory of carcinogensis. Br. J. Cancer 1954;8:1-12
113. Pinkel D, et al. Array comparative genomic hybridization and its applications in cancer. Nat. Genet. 2005;37:suppl.S11
114. Bardeesy N, et al. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol. Cell. Biol. 2001;21:2144-2153
115. Donehower LA, et al. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol. Carcinog. 1995;14:16-22
116. Hodgson G, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nat. Genet. 2001;29:459-464
117. Albertson DG, et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 2000;25:144-146
118. Sweet-Cordero A, et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes, Chromosomes Cancer 2006;45:338-348
119. Zhu C, et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 2002;109:811-821
120. Chadeneau C, et al. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 1995;55:2533-2536
121. Engelhardt M, et al. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin. Cancer Res. 1997;3:1931-1941
122. Odagiri E, et al. Reduction of telomeric length and c-erbB-2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer 1994;73:2978-2984
123. Meeker AK, et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am. J. Pathol. 2002;160:1259-1268
124. Meeker AK, et al. Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am. J. Pathol. 2004;164:925-935
125. van Heek NT, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol. 2002;161:1541-1547
126. Chin K, et al. In situ analyses of genome instability in breast cancer. Nat. Genet. 2004;36:984-988
127. Meeker AK, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin. Cancer Res. 2004;10:3317-3326
128. Meeker AK, et al. Recent advances in telomere biology: implications for human cancer. Curr. Opin. Oncol. 2004;16:32-38
129. Shpitz B, et al. Telomerase activity in ductal carcinoma in situ of the breast. Breast Cancer Res. Treat. 1999;58:65-69
130. O'Sullivan JN, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat. Genet. 2002;32:280-284
131. Rudolph KL, et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000;287:1253-1258
132. Miura N, et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet. 1997;93:56-62
133. Urabe Y, et al. Telomere length in human liver diseases. Liver 1996;16:293-297
134. Kitada T, et al. Telomere shortening in chronic liver diseases. Biochem. Biophys. Res. Commun. 1995;211:33-39
135. Zheng H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008;455:1129-1133
136. Artandi SE. Telomere shortening and cell fates in mouse models of neoplasia. Trends Mol. Med. 2002;8:44-47
137. Gonzalez-Suarez E, et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 2001;20:2619-2630
138. Stewart SA, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl Acad. Sci. USA 2002;99:12606-12611
139. Smith LL, et al. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat. Cell Biol. 2003;5:474-479
140. Armstrong L, et al. Overexpression of telomerase confers growth advantage, stress resistance, and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells 2005;23:516-529
141. Imamura S, et al. A non-canonical function of zebrafish telomerase reverse transcriptase is required for developmental hematopoiesis. PLoS One 2008;3:e3364
142. Yang C, et al. A key role for telomerase reverse transcriptase unit in modulating human embryonic stem cell proliferation, cell cycle dynamics, and in vitro differentiation. Stem Cells 2008;26:850-863
143. Fu W, et al. Anti-apoptotic role of telomerase in pheochromocytoma cells. J. Biol. Chem. 1999;274:7264-7271
144. Lee J, et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 2008;27:3754-3760
145. Masutomi K, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc. Natl Acad. Sci. USA 2005;102:8222-8227
146. Sarin KY, et al. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 2005;436:1048-1052
147. Flores I, et al. Effects of telomerase and telomere length on epidermal stem cell behavior. Science 2005;309:1253-1256
148. Choi J, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 2008;4:e10
149. Park JI, et al. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 2009;460:66-72
150. Gat U, et al. De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 1998;95:605-614
151. Lo Celso C, et al. Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development 2004;131:1787-1799
152. Van Mater D, et al. Transient activation of beta -catenin signaling in cutaneous keratinocytes is sufficient to trigger the active growth phase of the hair cycle in mice. Genes Dev. 2003;17:1219-1224
153. Maida Y, et al. An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature 2009;461:230-235
154. Savage SA, et al. Dyskeratosis congenita. Hematol. Oncol. Clin. North Am. 2009;23:215-231
155. Armanios M. Syndromes of telomere shortening. Annu. Rev. Genomics Hum. Genet. 2009;10:45-61
156. Vulliamy T, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413:432-435
157. Armanios M, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc. Natl Acad. Sci. USA 2005;102:15960-15964
158. Savage SA, et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am. J. Hum. Genet. 2008;82:501-509
159. Walne AJ, et al. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 2008;112:3594-3600
160. Vulliamy T, et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc. Natl Acad. Sci. USA 2008;105:8073-8078
161. Walne AJ, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum. Mol. Genet. 2007;16:1619-1629
|
Language: | English.
|
Document Type: | CANCER BIOLOGY.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0143-3334
|
NLM Journal Code: | c9t, 8008055
|
Annotation(s) | |
|
|